肾上腺消融术治疗原发性醛固酮增多症的应用与展望  

Application and perspective of catheter base-abrenal ablation for treatment of primary aldosteronism

作　　者：祝之明 孙芳 ZHU Zhiming;SUN Fang(Department of Hypertension and Endocrinology,Center for Hypertension and Metabolic Diseases,Daping Hospital,Army Medical University of PLA,Chongqing Institute of Hypertension,Chongqing 400042,China)

机构地区：[1]陆军军医大学大坪医院高血压内分泌科全军高血压代谢病中心重庆市高血压研究所,重庆400042

出　　处：《中国实用内科杂志》2024年第8期649-652,共4页Chinese Journal of Practical Internal Medicine

基　　金：国家自然科学基金(81920108010)。

摘　　要：原发性醛固酮增多症(primaryaldosteronism,PA)的患病率高,危害性大,但其筛查率较低,诊断与评估不够精准,药物和手术治疗均有一定的局限性。对不适于药物和手术治疗的PA患者,经皮肾上腺消融术是一个可选择的治疗措施,它具有疗效确切、安全及副反应少的特点。为有效治疗PA,可依据PA患者的临床特征及其意愿进行治疗策略评估,确定最适合的精准治疗方案,以减少副反应及其远期心脑血管风险。Primary aldosteronism(PA)has a high incidence and very harmful,but its screening rate is low,diagnosis and evaluation are imperfect,and tradtional treatments have certain limitations.For PA patients who are not suitable for medical and surgical treatment,percutaneous adrenal ablation is an optional treatment measure,which has the advantages of definite efficacy,being safe,and minimal side effects.To effectively treat PA,treatment strategies can be evaluated based on the clinical characteristics and willingness of PA patients to determine the most suitable treatment strategy,in order to avoid side effects and long-term cardiovascular and cerebrovascular risks.

关 键 词：原发性醛固酮增多症 治疗 经皮肾上腺消融术 

分 类 号：R544.1[医药卫生—心血管疾病]